Expanded Access Programs (EAPs) allow patients with serious or life-threatening conditions to obtain investigational treatments outside of the clinical trial setting. Because they are not formal clinical trials, EAPs do not require as much data [...]
Expanded/Early Access (EA), Compassionate Use (CU) and Named Patient Use (NPU) are critical pathways for patients with serious or life-threatening conditions to obtain investigational treatments outside of clinical trials. While these programs offer hope for [...]
Earlier this month, WEP Clinical had the incredible opportunity to participate in the prestigious World Economic Forum (WEF) Davos event, as a proud sponsor of the Partner for Patient conference, HEAL - Health Equity Action [...]
Interested in collecting data during your access program, but haven’t decided on what you would like to use it for? Let WEP help provide some guidance. While there aren’t specific regulations that guide the collection [...]
Previously, I discussed common challenges faced by Sponsors dissatisfied with their access program vendor's service. You can read the full article by clicking here.If any of these issues resonate with you, know that you're not [...]
Feeling dissatisfied with the level of service provided by an Access Program vendor is not uncommon for pharmaceutical and biotech companies. Many Sponsors that choose to outsource the management of their access program(s), be it [...]
In today’s fast-paced pharmaceutical landscape, selecting the right partner for your clinical trials is crucial. Here are some compelling benefits of opting for a small CRO: Personalized AttentionSmall CROs often provide tailored solutions and dedicated [...]
In the world of pharmaceutical development, Expanded Access Programs (EAPs) and Post-Trial Access (PTA) initiatives play a crucial role in delivering life-saving therapies to patients in need. These programs are essential for providing access to [...]
Expanded Access Programs (EAPs) are used to provide controlled and compliant access to investigational drugs for patients outside of the clinical trial setting. Many Sponsors choose to offer EAPs altruistically, as a critical treatment pathway [...]
Selecting the right CRO is crucial for biotech companies, as it can significantly impact the success of clinical trials and, ultimately, the development of new therapies. There are key reasons why value-added services are important [...]
